1
项与 Autologous Bone Marrow CD34+ Stem Cells (Emmes) 相关的临床试验Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 1 year.
100 项与 Autologous Bone Marrow CD34+ Stem Cells (Emmes) 相关的临床结果
100 项与 Autologous Bone Marrow CD34+ Stem Cells (Emmes) 相关的转化医学
100 项与 Autologous Bone Marrow CD34+ Stem Cells (Emmes) 相关的专利(医药)
100 项与 Autologous Bone Marrow CD34+ Stem Cells (Emmes) 相关的药物交易